Midcap advisors

From Deliveries to Deals – Episode 1:

MidCap Advisors’ Managing Director of Healthcare, Scott Yoder, sits down with Dr. Jean Fitzgerald of Doylestown Women’s Health to discuss the journey of building a successful independent OB/GYN practice and the factors that led the group to pursue a strategic partnership. With more than 41 years of experience as a board-certified obstetrician and gynaecologist, Dr Fitzgerald shares insights on navigating the evolving women’s health landscape, managing a competitive sale process, and reflecting nearly two years after closing.

Compensation Is a Valuation Variable: Physician compensation is one of the most complex and consequential elements of an OB/GYN practice valuation. In a transaction, buyers will normalize physician compensation to fair market value (FMV), which means that owner compensation that is either well above or well below market rates will be adjusted in the financial model. For a practice owner who has been drawing a below-market salary to maximize distributions, this normalization can reduce normalized EBITDA, which is unfavorable. But for a practice with multiple physicians compensated at above-market rates, the normalization adjustment will increase EBITDA and increase value. Understanding the relationship between your current compensation structure and the buyer’s normalization process is essential planning knowledge.

Retaining Talent Through Transition

Physician retention is among the most significant post-acquisition risks that PE buyers manage in physician practice transactions. A practice in which key physicians are not contractually committed beyond closing poses a material earnings risk that buyers will discount. Most PE-backed transactions include employment agreements for all key physicians that run for 3 to 5 years post-close, with compensation structured to maintain productivity incentives while aligning with the broader platform’s financial targets. Practices that can deliver long-term physician agreements as part of a transaction de-risk the transaction and can earn a meaningful multiple premium.

Compensation Design for the Post-Sale Environment

After a PE-backed sale, physician compensation typically shifts from a simple ownership draw or equal-share model to a layered structure that includes a base salary (usually set below current draw), productivity-based incentives tied to wRVUs or collections, practice-wide profit sharing (EBPC-based), potential equity rollover in the combined platform, and value/quality bonuses tied to outcomes metrics. Understanding this post-transaction compensation architecture before entering negotiations allows physician-owners to model their expected post-close earnings and evaluate deal terms on a fully-loaded basis—not just the headline transaction multiple.

Alignment as a Strategic Asset

The ideal pre-sale compensation structure aligns physician incentives with practice growth, retains clinical talent during the transition period, and presents buyers with a predictable, scalable earnings model. Achieving that alignment requires thoughtful design, physician buy-in, and ideally external compensation benchmarking data. Engaging a healthcare compensation consultant or transaction advisor in the 12 to 24 months prior to a planned sale is a high-return investment that can pay dividends not only in valuation but in transaction speed and certainty.

A Market Poised for Renewed Momentum: As 2026 unfolds, the women’s health M&A market is entering a period of renewed momentum following two years of calibration and normalization after the 2021-2022 transaction peaks. Multiple macroeconomic and structural forces are converging to support increased deal activity: stabilizing interest rates are improving acquisition financing conditions, record levels of PE dry powder are seeking deployment, improving public equity market conditions are creating a clearer path to future PE exits, and the demographic and structural fundamentals underlying women’s health demand continue to strengthen. KPMG’s 2026 Healthcare & Life Sciences Investment Outlook reports that 67% of healthcare and life sciences dealmakers surveyed anticipated increased M&A activity in 2026.

Platform Activity: The Nine Major Players and What Comes Next

The nine major PE-backed women’s health platforms operating in the U.S. as of early 2026 are at varying stages of their investment cycles. As platforms mature and PE sponsors approach the end of their typical holding periods, secondary sales, larger strategic combinations, and potential public-market exits via IPOs will become increasingly relevant. The reopening of the healthcare IPO market, with Hinge Health and Omada Health going public in the summer of 2025, signaled renewed investor appetite for healthcare services assets, creating a potential exit pathway for the largest and most mature women’s health platforms. This secondary transaction activity will itself generate new investment opportunities as assets are repositioned and repackaged.

Emerging Service Lines: Where Growth Is Going

The platforms that will command the highest exit multiples in the next 5 to 7 years will be those that successfully execute multi-specialty expansion strategies. Fertility services, behavioral health integration, menopause and longevity medicine, and AI-enabled diagnostics are the service categories most frequently cited by investors and operators as the highest-priority growth vectors. The global “FemTech” industry, software and technology addressing women’s biological needs, was expected to grow to $75 billion by 2025 at a 13.3% compound annual growth rate since 2020, and its continued expansion is creating new investment and integration opportunities for clinical platforms. OB/GYN practices that are already building out these service lines today will be more attractive acquisition targets for established platforms—and will benefit from higher multiples that reflect the diversified earnings potential.

Regulatory Environment: Navigating Uncertainty

The regulatory environment for physician practice M&A is increasingly complex. State-level oversight legislation, ongoing federal scrutiny of PE in healthcare, evolving Stark Law and Anti-Kickback enforcement priorities, and continued uncertainty around Medicaid reimbursement policy all represent headwinds that buyers must underwrite, and sellers must understand. PwC’s 2026 healthcare M&A outlook notes that buyers are demonstrating disciplined capital deployment in this environment, favoring high-quality, cash-generating assets with clear reimbursement visibility and avoiding areas subject to shifting regulatory dynamics. For OB/GYN practice owners, the practical implication is clear: a well-run, compliant practice with a diversified, commercially weighted payer mix will be a more attractive and more highly valued transaction target than a comparable practice with compliance risk or payer mix uncertainty.

The Window for Independent Practice Owners

The most important forecast for independent OB/GYN practice owners is this: the window of maximum investor interest in women’s health is open now, and the practices that engage in strategic planning today will be best positioned to participate on favorable terms. Nine major platforms are being built, hundreds of millions in PE capital are allocated specifically to women’s health acquisitions, and demographic demand for comprehensive women’s health services continues to accelerate. For practice owners who have invested years in building a high-quality, well-run clinical practice, the current environment represents a genuine opportunity to realize that value, with the right preparation, the right process, and the right advisors by their side.

The Advisor Selection Decision: Selecting the right investment banking advisor for your practice sale is one of the most consequential decisions in the entire transaction process. The right advisor will help increase the practice’s value before going to market, design and manage a competitive sale process, identify and reach all relevant buyers, position your practice compellingly in a Confidential Information Memorandum (CIM), drive competitive tension that maximizes price, negotiate deal terms that protect your interests, and guide you through a complex transaction from engagement letter through closing. The wrong advisor will cost you time, money, and potentially the transaction itself.

Healthcare Specialization Is Non-Negotiable

Physician practice M&A is a specialized discipline with its own regulatory landscape (Stark Law, Anti-Kickback, state corporate practice of medicine laws), its own valuation methodology (normalized EBITDA, fair market value compensation, quality-of-earnings adjustments), and its own buyer universe (PE sponsors with healthcare-specific theses, hospital systems, health plans). A generalist M&A advisor who lacks deep healthcare transactional experience will struggle to navigate these complexities effectively. Meaningful healthcare deal experience, ideally including specific women’s health or OB/GYN transactions, is a minimum qualification threshold, not a differentiating attribute.

Track Record and Buyer Relationships

The quality of an advisor’s buyer relationships is a direct determinant of the competitive tension they can create in your sales process. A firm with established relationships across the full universe of relevant women’s health PE platforms, healthcare-focused PE funds, hospital systems, and strategic consolidators can generate more competitive offers than a firm with limited buyer reach. Ask prospective advisors for specific references from recently closed physician practice transactions and follow up directly with those references to assess the advisor’s process quality, responsiveness, and effectiveness under pressure.

Alignment of Incentives

Investment banking fee structures should align the advisor’s incentives with the seller’s objectives. Most healthcare M&A advisors charge a success fee based on the total transaction value, a structure that motivates advisors to maximize price. Be cautious of advisors who propose flat retainer arrangements without meaningful success fee components, or who have financial relationships with buyers that could create conflicts of interest. The relationship between your investment banker and the buyers they recommend should be transparent, disclosed, and free of material conflicts.

The Value of a Dedicated Advocate

Perhaps the most important quality to assess in a prospective investment banking advisor is their commitment to serving as a genuine advocate throughout the process. Healthcare transactions are inherently stressful, involve significant information asymmetry, and require sustained attention and expertise across financial, legal, operational, and interpersonal dimensions simultaneously. An advisor who has managed multiple physician practice transactions through successful closings, has seen the full range of challenges that arise in complex deals, and knows how to navigate them is invaluable. The most important question to ask a prospective advisor is simple: who specifically on your team will be working on my transaction, and what is their relevant experience?

The Closing Is Not the End—It Is the Beginning: For many physician owners, the closing of the transaction represents the culmination of a multi-year planning and preparation process. But for the PE sponsor acquiring the practice, closing day is day one of a 5- to 7-year value-creation effort. Understanding what the post-closing period entails and what physicians should expect regarding their professional life, compensation, autonomy, and relationship with the new ownership is essential context for evaluating any transaction opportunity before it is consummated.

The First 100 Days: Integration Priorities

The initial 100 days following a PE acquisition are typically the most intensive from an operational standpoint. PE sponsors generally move quickly to implement shared administrative infrastructure, integrate the practice’s financial reporting into the platform’s management systems, and identify early synergy opportunities. For physicians, this period often involves a transition from the familiar rhythms of independent practice management to operating within a more structured corporate governance environment, with monthly financial reporting, KPI tracking, and regular interaction with PE firm operating partners and portfolio management teams.

Employment Agreements and Compensation Transition

Almost universally, physicians who sell their practices to PE-backed platforms enter into formal employment agreements at closing. These agreements typically run 3 to 5 years and include a base salary, productivity incentives tied to wRVUs or collections, participation in practice-wide profit sharing, and post-closing restrictive covenants (non-competes, non-solicitation). The transition from practice owner to employed physician, even a highly compensated employed physician with significant rollover equity, represents a meaningful shift in professional identity and daily operational reality. Physicians who understand and anticipate this transition are better positioned to navigate it successfully.

Clinical Autonomy: What to Expect

One of the most common concerns among physicians considering a PE transaction is the potential impact on clinical autonomy. The degree to which clinical autonomy is preserved post-transaction varies significantly across PE sponsors and platform operators. The strongest platforms have recognized that physician satisfaction and clinical culture are directly linked to patient retention, physician recruitment, and practice EBITDA, all of which PE sponsors care deeply about. The practices that have successfully negotiated and documented specific clinical governance provisions in their employment and transaction agreements, including rights regarding hiring, clinical protocols, and patient care standards, have generally fared better on the autonomy dimension than those that relied on informal assurances.

The Exit and the Second Bite

For physicians who retained rollover equity at closing, the PE sponsor’s eventual exit is the next major financial event of the transaction cycle. PE holding periods have been extending in recent years, with many healthcare platforms now anticipating 5 to 7 year holds before a secondary sale or other exit. When the exit occurs, physicians holding rollover equity will receive their proportional share of exit proceeds, potentially generating significant returns if the platform has grown successfully. Physicians considering a transaction should model the expected rollover equity return over realistic holding periods and under multiple assumptions as part of their overall transaction evaluation.

The Economics of a Physician Practice Transaction: For most OB/GYN practice owners, a transaction with a PE-backed platform or strategic buyer will be the largest single financial event of their professional lives. Understanding the components of a transaction structure, how the purchase price is allocated across different consideration types, what obligations and opportunities each component entails, and how the total economic value of a deal should be evaluated is fundamental to making an informed decision. No two transactions are identical, but the key structural elements are consistent.

Cash at Close: The Liquidity Event

Cash at close refers to the immediate, lump-sum payment the seller receives at the closing of the transaction. In most physician practice PE transactions, this represents the largest single component of consideration, typically between 51% and 80% of the total enterprise value, depending on the deal structure and the buyer’s expectations for physician equity participation. Cash at close proceeds from the sale of a practice are generally eligible for long-term capital gains tax treatment when structured as a sale of equity or goodwill, which significantly enhances their after-tax value relative to ordinary income. Maximizing cash at close is typically a priority for physicians nearing retirement or with limited post-close investment flexibility.

Rollover Equity: The Second Bite

Rollover equity is the portion of enterprise value that sellers retain as an ownership stake in the combined, PE-backed entity rather than receiving as immediate cash. In a typical majority recapitalization, sellers roll over 20% to 49% of their transaction value into the new platform. This equity is generally held until the PE sponsor exits its investment, typically in 3 to 7 years, at which point sellers receive their proportional share of the exit proceeds. If the PE sponsor has successfully grown the platform’s EBITDA and achieved multiple expansion, the rollover equity can generate returns that substantially exceed the original investment. For example, rolling $3 million of proceeds into a platform that subsequently sells for a 2x equity return would generate $6 million in rollover proceeds, a highly meaningful “second bite of the apple.” The risk, of course, is that rollover equity is illiquid until the platform exit, and returns are not guaranteed.

Earnouts: Bridge the Gap, Accept the Risk

Earnout provisions are contingent payments that become payable post-closing if the practice achieves certain financial or operational milestones, typically revenue growth targets, EMR implementation, EBITDA thresholds, or patient volume metrics. Earnouts serve as a valuation bridge when buyer and seller have different views of the practice’s future earnings potential. They allow buyers to underwrite a higher total transaction value while limiting the risk of overpaying for performance that does not materialize. For sellers, earnouts offer the potential for additional upside but carry meaningful risk, because earnout payments depend on performance outcomes that may be influenced by buyer integration decisions, market dynamics, and operational changes that are partially or fully outside the seller’s control. In healthcare transactions, in particular, earnouts must be carefully structured to avoid creating financial incentives that could implicate federal fraud and abuse laws.

Evaluating Total Economic Value

When evaluating a transaction offer, sophisticated sellers should model the total economic value across all consideration types under multiple scenarios, conservative, base, and optimistic, for both earnout achievement and rollover equity returns. The headline EBITDA multiple is a useful benchmarking tool, but it does not tell the complete story. Two offers with the same headline multiple can have very different economics depending on how consideration is allocated among cash, rollover, and earnout. Your investment banking and legal advisors should help you build this economic model before you make any negotiating decisions.

Two Very Different Buyer Types: In the OB/GYN M&A market, practice owners will primarily encounter two categories of buyers: strategic buyers (typically hospital systems, health networks, or larger physician group consolidators) and financial buyers (private equity sponsors). Understanding the fundamental differences between these buyer categories in terms of their objectives, deal structures, operational philosophies, and financial capacity is essential to evaluating any offer and selecting the right partner for your post-transaction professional life.

Strategic Buyers: Integration and Synergy

Strategic buyers are acquiring practices because the addition creates operational or strategic value for their existing enterprise. A hospital system acquiring an OB/GYN practice is typically seeking to control referral patterns, integrate the practice into its employed physician network, and leverage the practice’s patient base to drive utilization of the system’s inpatient and ancillary services. Strategic buyers can sometimes justify higher prices when synergies are significant, but they are also acquiring to integrate, which typically means the practice will be absorbed into the buyer’s operational model, governance structure, and compensation system. Clinical autonomy and practice culture are frequent casualties of strategic acquisitions.

Private Equity Buyers: Growth and Returns

Private equity groups are financial investors that acquire physician practices as part of a broader value-creation strategy. They are not acquiring to integrate into an existing operational infrastructure—they are acquiring to build a platform, grow EBITDA over a 3-to-7-year holding period, and ultimately sell the larger, more valuable platform to a subsequent buyer (often a larger PE fund or strategic acquirer). Because PE sponsors are underwriting future growth, not current synergies, they price acquisitions primarily on normalized EBITDA multiples and are motivated to present deal terms that retain physician talent and incentivize continued clinical productivity through rollover equity and attractive post-closing compensation.

Culture, Control, and Clinical Autonomy

One of the most significant differentiators between strategic and PE buyers is the degree of operational control and cultural preservation that each model offers. Strategic buyers, particularly hospital systems, tend to be more prescriptive about employment arrangements, governance, and clinical protocols. PE-backed platforms, by contrast, often market themselves on their commitment to preserving physician autonomy and practice culture, at least in the near term. In practice, the degree of autonomy varies significantly across PE sponsors and platforms, and physician-owners should speak directly with physicians at other practices within any PE platform under consideration before making a decision.

Which Is Right for Your Practice?

The optimal buyer type depends heavily on the age composition of your physician group, your financial objectives, your post-transaction professional goals, and your practice’s strategic position in the local market. A group of physicians who are 5 to 10 years from retirement, with significant rollover equity upside, may find a PE transaction more financially compelling. A group whose founder is closer to full retirement and values income stability and the elimination of business risk may find strategic employment more attractive. Running a competitive process rather than negotiating exclusively with one buyer type remains the most reliable strategy for ensuring you achieve the best possible outcome across all dimensions.

The Cost of Avoidable Mistakes: Healthcare M&A transactions are complex, high-stakes, and often once-in-a-career events for physician-owners. The asymmetry of experience between a practice owner making their first sale and a sophisticated PE buyer who has executed dozens of transactions poses significant risk for sellers who are not properly advised. Understanding the most common valuation mistakes and how to avoid them can make the difference of millions of dollars in final transaction value.

Mistake #1: Underestimating EBITDA Adjustments

EBITDA adjustments are new growth annualized and expenses that are legitimately excluded from normalized EBITDA because they are non-recurring, owner-specific, or above-market. Common add-backs for OB/GYN practices include above-market owner compensation, personal expenses (automobile, travel, and entertainment), one-time legal settlements, non-recurring equipment purchases, and excessive depreciation. Many practice owners fail to identify and document all legitimate add-backs, leaving meaningful value on the table. A well-prepared sell-side quality-of-earnings analysis conducted by your advisors before buyers conduct their own ensures that every legitimate add-back is identified, documented, and defended.

Mistake #2: Engaging with the First Buyer Who Calls

One of the costliest mistakes a practice owner can make is accepting an unsolicited offer without running a competitive process. PE platforms routinely make unsolicited, off-market approaches to attractive OB/GYN practices, often framing the arrangement as a partnership opportunity and emphasizing the benefits of early engagement. These approaches almost always result in pricing at or below the lower end of market value, because the buyer has no competitive pressure to bid aggressively. A structured, competitive sale process managed by an experienced healthcare investment banker reaching all relevant buyers simultaneously has been shown to achieve meaningfully higher transaction values. Numerous studies indicate practices represented by M&A advisors achieve, on average, a 25% higher multiple from buyers.

Mistake #3: Ignoring Tax Implications

The structure of a physician practice transaction has profound tax implications that can dramatically affect net proceeds. Most PE transactions are structured through a Management Services Organization (MSO) using asset purchase mechanics, which allows buyers to obtain a stepped-up tax basis on acquired assets. For sellers, asset sales are taxed differently than equity sales, and the allocation of purchase price among different asset categories (goodwill, non-compete agreements, equipment, receivables) can significantly affect the character and timing of tax recognition. Engaging a CPA with healthcare M&A transaction experience well before closing not the week before is essential for structuring the transaction to minimize the seller’s tax burden.

Mistake #4: Letting Due Diligence Surprises Derail the Deal

The most common deal-killers in physician practice transactions are due diligence surprises, issues that buyers discover during their investigation that were not disclosed or apparent in the seller’s initial presentation. Common surprises include undisclosed compliance issues (e.g., improper billing for ancillary services), outstanding malpractice claims without adequate tail coverage, and physician contract terms that create post-closing liabilities. Conducting a thorough pre-sale due diligence review, essentially a self-audit, before engaging buyers allows practice owners to identify and address these issues proactively, rather than having them surface as negative surprises that erode buyer confidence and reduce price.

Mistake #5: Undervaluing Non-Financial Terms

Sophisticated sellers understand that transaction value is not only about the headline purchase price multiple. Post-closing employment agreement terms, non-compete scope and duration, tail malpractice coverage obligations, working capital targets and true-up mechanisms, representations and warranties provisions, and rollover equity structure can each materially affect the seller’s economic outcome and post-closing professional experience. Ensuring that your legal advisor has deep healthcare M&A transaction experience, not just general corporate legal experience, is essential to negotiating deal terms that protect your interests across the full range of transaction documents.

The Earlier You Start, the Better Your Outcome: One of the most consistent pieces of advice from healthcare investment bankers and practice M&A advisors is deceptively simple: start preparing earlier than you think you need to. The practices that achieve the highest valuations and the cleanest transaction executions are those that begin preparing 18 to 36 months before formally engaging with buyers. This timeline enables meaningful value-creation activities, financial cleanup, operational optimization, ancillary service integration, physician contracting, and leadership development to be implemented and reflected in trailing financial statements before buyers arrive.

Year One: Foundation Building

The first year of pre-sale preparation should focus on establishing the financial and operational foundation that a sophisticated buyer will expect. This includes normalizing financial statements, benchmarking physician compensation against published FMV surveys, conducting a revenue cycle audit to identify opportunities for billing and coding optimization, and evaluating your current physician contracts for retention risk. It is also the appropriate time to engage a healthcare attorney to review your corporate structure, ensure compliance with applicable regulations, and assess any legacy liability issues that could surface in due diligence.

Year Two: Value Creation Execution

The second year should focus on executing the value creation initiatives identified in year one. If ancillary services are a strategic priority, this is the window to implement them ideally with at least 12 months of operating history before a formal sale process begins. If physician succession is a concern, this is the time to recruit and onboard younger partners, establish their patient relationships, and execute long-term employment agreements. If revenue cycle performance is below benchmark, this is the window to implement process improvements and document the resulting financial improvement.

Six Months Out: Process Preparation

In the six months before formally launching a sale process, the focus shifts to process preparation. This includes engaging an investment banking advisor to conduct a preliminary valuation analysis and market assessment, beginning the preparation of a Confidential Information Memorandum (CIM) that tells your practice’s story in a compelling, buyer-ready format, and assembling the data room materials that buyers will request during diligence five years of financial statements, tax returns, payer contracts, lease agreements, physician employment contracts, malpractice claims history, and compliance documentation. The quality and completeness of your data room materials is a direct signal to buyers about how well-managed your practice is.

The Transaction Window

Healthcare M&A markets are cyclical. The current environment, with nine active women’s health platforms competing for high-quality acquisition targets, over $1.3 trillion in undeployed PE capital globally, and improving deal market conditions in 2026, according to PwC, represents a favorable window for OB/GYN practice owners considering a transaction. Market conditions will change. Interest rate environments shift. Buyer appetite waxes and wanes with PE fund cycles. The practice owners who achieve the best outcomes are those who are transaction-ready when the market is most favorable, not those who begin their preparation after the optimal window has passed.

Beyond the Core Visit: The traditional OB/GYN practice model, built around prenatal care, delivery, and routine gynecological visits, generates a solid revenue base but offers limited margin expansion without adding providers or locations. The introduction of ancillary services fundamentally changes that equation. By integrating high-margin, in-house services that leverage existing patient relationships and clinical infrastructure, OB/GYN practices can grow EBITDA substantially without proportionate increases in overhead. And because ancillary revenue diversifies the earnings stream and increases revenue per patient visit, it also makes the practice more attractive to buyers—and commands a higher valuation multiple.

The Economics of Ancillary Integration

The Medical Group Management Association (MGMA) has found that practices that integrate ancillary services generate 15% to 25% higher net revenue per provider than those that do not. In an environment where Medicare physician payment rates have declined approximately 26% in real terms since 2001, ancillary revenue has become a critical offset to reimbursement compression. Owned ancillary services, such as labs, ambulatory surgery centers, imaging, pathology, and other in-house services, commonly add 1X to 3X of EBITDA multiples in physician practice transactions. At a $3 million EBITDA base, a 2-turn multiple expansion equates to $6 million in additional enterprise value.

Aesthetics, Menopause Care, and Ultrasound

Beyond fertility, OB/GYN practices have a natural advantage in patient relationships in adjacent service categories. The global OB/GYN ultrasound devices market was valued at $2.13 billion in 2024 and is projected to reach $2.84 billion by 2030, growing at nearly 5% annually, according to Grand View Research. 3D/4D imaging systems are the fastest-growing segment. In-house ultrasound keeps revenue that would otherwise flow to hospital outpatient departments or independent imaging centers within the practice and demonstrates to buyers the operational integration that supports premium valuations. Menopause care and hormone therapy represent another growing category driven directly by demographic trends: the fastest-growing cohort of women is those over 65.

Compliance Considerations

Ancillary service integration in physician practices is subject to important legal constraints, including the Stark Law’s in-office ancillary exception, the Anti-Kickback Statute, and applicable state laws governing physician self-referral. Practices adding ancillary revenue streams should engage healthcare legal counsel to ensure compliance with all applicable regulations, both because noncompliance represents a real legal risk and because buyers will conduct thorough compliance due diligence as part of any acquisition process. A practice with well-documented, compliant ancillary service operations presents a cleaner and more attractive acquisition target than one where compliance structures are informal or incomplete.

Value Is Created Before the Process Begins: One of the most consistent findings in healthcare M&A is that the practices that achieve the highest valuations are those that invested meaningful time and resources in pre-sale preparation, often 18 to 36 months before formally entering a process. The moment you engage with potential buyers, the narrative is largely set. The financial statements are what they are; the operational profile is established; the payer contracts are in place. Buyers will underwrite what they observe. The highest-leverage moment to influence your valuation outcome is before the process begins, not during it.

Financial Hygiene: Clean Books, Clean Story

The first and most foundational step in pre-sale preparation is establishing clean, audit-ready financial statements. This means separating personal expenses from practice operations, normalizing owner compensation to fair market value, documenting all add-backs with supporting receipts and explanations, and ensuring that your chart of accounts clearly reflects the practice’s underlying economics.

Operational Efficiency as a Value Driver

Revenue cycle optimization is one of the most direct paths to EBITDA improvement, and therefore to higher valuation. Practices that reduce claims denial rates, accelerate collections, and eliminate coding errors can capture meaningful incremental revenue without adding clinical volume. Similarly, supply chain renegotiation, staffing ratio optimization, and overhead cost reduction can each add meaningful basis points to EBITDA margins.  Practices represented by M&A advisors or investment banks achieved, on average, a 25% higher multiple from buyers, a premium largely attributable to pre-market optimization and competitive process management.

Leadership Structure and Succession Planning

Buyers evaluate practices not just as financial assets but as operating businesses that must continue to generate earnings after closing. A practice where all clinical leadership and patient relationships are concentrated in one or two founding physicians presents a concentration risk that buyers will discount. Building a second tier of physician leadership with younger partners who have long-term agreements, administrative responsibilities, and demonstrated patient loyalty is one of the most durable value creation strategies available to OB/GYN practice owners. This process takes time, which is why starting early matters.

Documenting Your Growth Story

Buyers pay for future earnings, not just historical performance. A practice that can articulate a credible, data-supported growth narrative, whether through geographic expansion, service line addition, provider recruitment, or payer contract improvement, will consistently achieve higher valuations than a comparable practice with no visible growth pathway. Work with your advisors to build a coherent growth model grounded in realistic assumptions and supported by documented market data. This narrative serves as the foundation of the Confidential Information Memorandum (CIM), which drives buyer interest and competitive tension in a formal sale process.

Valuation Is a Financial Conversation: When a sophisticated buyer evaluates an OB/GYN practice, they are not making an intuitive judgment about its quality; they are constructing a financial model. That model is anchored by a discrete set of metrics that determine how much EBITDA the practice generates on a normalized, sustainable basis, and what multiple the market will pay for that earnings stream. Understanding these metrics is the first step toward understanding your practice’s value, and toward taking actions that can meaningfully increase it before going to market.

1. Normalized EBITDA

Normalized EBITDA, earnings before interest, taxes, depreciation, and amortization, adjusted for non-recurring items and owner-specific expenses, is the single most important driver of practice value. Buyers will add back legitimate one-time expenses (such as a one-time legal settlement or a non-recurring capital expenditure), normalize owner compensation to fair market value, and adjust for personal expenses run through the practice. The resulting normalized EBITDA is the denominator in the multiple equation: if your practice generates $3 million in normalized EBITDA and the applicable market multiple is 8x, your practice is worth approximately $24 million. A single turn of multiple or $250,000 of additional normalized EBITDA represents $2 million in enterprise value.

2. Revenue Per Provider

Revenue per physician (or per full-time equivalent provider) is a key operational benchmark that buyers use to assess productivity and identify upside potential. A practice whose revenue per provider lags its peer group may be underperforming in scheduling efficiency, billing capture, or coding optimization, which represent identifiable opportunities for improvement. Conversely, a practice with above-average revenue per provider demonstrates strong operational management and is likely to attract premium valuation attention.

3. Payer Mix

As discussed in earlier articles, payer mix is a critical quality-of-earnings consideration. Buyers consistently apply a premium to practices with a high proportion of commercial insurance revenue and apply discounts to practices with heavy Medicaid or self-pay exposure. Improving your payer mix through targeted marketing, managed care contracting, and selective patient acquisition strategies can meaningfully increase your practice’s attractiveness to buyers and the multiple they are willing to pay.

4. Working Capital and Revenue Cycle Efficiency

Buyers will examine accounts receivable aging, claims denial rates, and days in A/R as indicators of revenue cycle health. The Medical Group Management Association (MGMA) has found that 86% of claim denials are avoidable, yet nearly 24% of denied claims are never successfully reworked. A practice with a high denial rate, aged receivables, or slow collection cycles signals management risk to buyers and can trigger a working capital adjustment that reduces net proceeds at closing. Clean, efficient revenue cycle operations are both a valuation driver and a due diligence risk mitigation strategy.

5. Physician Retention and Contract Structure

Buyer underwriting is fundamentally about earnings durability. A practice in which key physicians operate without long-term agreements, are nearing retirement age, or have expressed an intention to reduce their clinical activity, poses a revenue risk that buyers will price into their offers. Practices where younger physicians are under long-term agreements, where leadership depth extends beyond the founding generation, and where clinical schedules are well-documented and sustainable consistently achieve 1X to 2X higher multiples than comparable practices with physician continuity risks. Investing in physician retention and succession planning before going to market is one of the highest-return value creation activities available to practice owners.

The Hospital Employment Trend: For much of the past two decades, hospital systems have aggressively recruited OB/GYN physicians into employment arrangements, offering salary guarantees, malpractice coverage, and administrative support in exchange for integrating their practices. By 2024, fewer than half of all U.S. physicians remained truly independent, with approximately 78% now employed by hospitals, health systems, insurers, private equity-backed entities, or other corporate employers, according to Baldwin CPAs. In OB/GYN specifically, the combination of high malpractice risk, Medical Economics reports that 62% of OB/GYNs will face legal action at some point, the highest rate of any specialty, and increasing administrative burdens have historically made hospital employment an attractive option for physicians seeking reduced operational risk.

Hospital Systems as Strategic Buyers

Hospital systems today are not merely recruiting individual physicians; they are actively acquiring OB/GYN practices as strategic assets. Hospital ownership of OB/GYN practices allows health systems to control referral patterns for high-margin services, including surgical procedures, imaging, laboratory, and inpatient care. It also enables systems to build maternity service lines that drive broader patient acquisition and loyalty. Hospital-physician consolidation reached 66% in the Midwest in 2024 and 58% in rural areas, according to data cited by Becker’s Healthcare, illustrating the scale of health system physician integration strategies.

The Pros and Cons of Health System Affiliation

For an independent OB/GYN practice owner weighing strategic options, health system affiliation offers certain genuine advantages: income stability, elimination of practice management overhead, malpractice coverage, and access to hospital resources. However, affiliation with a health system typically comes at a high-cost relative to a private equity transaction. Health systems generally cannot offer the same upfront liquidity event as a PE-backed sale. They rarely offer rollover equity or the “second bite of the apple” that PE recapitalizations provide. And clinical autonomy, once surrendered to a hospital system, is notoriously difficult to preserve under employment models that prioritize system-level efficiency and standardization.

The Private Sale Advantage

By contrast, a well-structured private sale to a PE-backed platform or strategic consolidator can generate immediate capital liquidity at fair market value, provide meaningful rollover equity in the combined entity, and, importantly, allow physicians to maintain greater influence over clinical protocols and practice culture, at least in the near term. For a physician group that is 5 to 10 years from full retirement, the economics of a PE transaction, including the potential for a significant second bite return when the platform is ultimately sold, can substantially exceed the present value of a hospital employment arrangement.

Evaluating Your Options

The choice between hospital employment, PE affiliation, or continued independence is deeply personal and practice-specific. Key variables include the age and composition of the physician group, local market dynamics, existing payer mix, real estate and lease obligations, malpractice tail coverage costs, and individual financial planning priorities. The most important step any practice owner can take is to obtain a clear, unbiased assessment of their practice’s value in the current market before making any strategic commitment. Engaging an experienced, healthcare-focused investment banking advisor to run a structured process remains the most reliable way to ensure that all available options are properly evaluated.

The Reimbursement Reality: Physician reimbursement has been under persistent structural pressure for decades. Medicare physician payment rates have effectively declined by approximately 26% since 2001, when adjusted for inflation, according to the Medical Group Management Association. For OB/GYN practices, which rely heavily on global obstetric billing codes and face ongoing scrutiny of evaluation and management (E&M) services, these reimbursement dynamics are not abstract policy issues; they directly affect EBITDA, which determines practice value. A buyer underwriting an OB/GYN acquisition today must carefully evaluate the sustainability of current revenue levels, considering potential future rate adjustments.

Payer Mix and Valuation Discounts

In physician practice M&A, payer mix is widely considered one of the most consequential Quality-of-Earnings (Q of E) factors. Practices with predominantly commercial insurance revenue command a significant premium, often 40% to 60% higher multiples than practices with heavy Medicaid or government payer exposure. For OB/GYN practices, this is a particularly salient issue: maternity care has disproportionately high Medicaid participation rates, and Medicaid reimbursement rates for obstetric services vary substantially by state. In states with low Medicaid rates and high Medicaid patient volumes, buyers will apply meaningful discounts to reflect the earnings risk. Understanding your payer mix composition and its trajectory is a prerequisite to accurate practice valuation.

Regulatory Pressures Specific to Women’s Health

The post-Dobbs regulatory environment has introduced new dimensions of uncertainty into the OB/GYN practice landscape. State-level abortion restrictions have had measurable effects on physician recruitment, with the average number of applications per OB/GYN residency program declining from 661 in 2022 to 585 in 2024, with particularly sharp decreases in states that adopted complete abortion bans, according to AMB Wealth’s OB-GYN Industry Primer. These workforce dynamics have downstream valuation implications: practices in restrictive-legislation states may face greater physician recruitment challenges and potential volume uncertainty, both of which buyers will factor into their underwriting assumptions.

State-Level PE Oversight Legislation

An emerging regulatory risk for physician practice transactions is the wave of state legislation targeting private equity’s role in healthcare. Massachusetts enacted comprehensive healthcare transaction review legislation in late 2024, requiring detailed reporting and extending review timelines up to 215 days for certain PE-healthcare transactions. Connecticut, Maine, and New York have proposed similar legislation that would impose new notice requirements and operational restrictions. While these regulations have not halted deal activity, they have increased transaction complexity, extended timelines, and elevated compliance costs for buyers—factors that can influence deal structure, terms, and ultimately price.

Preparing Your Practice for Reimbursement Scrutiny

Buyers conducting quality-of-earnings due diligence will examine reimbursement sustainability as a central pillar of their analysis. Practice owners who want to maximize valuation should proactively document their revenue cycle management processes, demonstrate rigor in payer contract management, and be prepared to articulate their exposure to, and mitigation strategies for, reimbursement risk. Practices that can demonstrate a commercially weighted, diversified payer mix, ideally with a growing proportion of fee-for-service commercial business, will consistently achieve superior transaction outcomes.

From Independent Practices to Regional Platforms: Across the United States, a fundamental transformation is reshaping the women’s health landscape: the aggregation of independent OB/GYN practices into large, multi-location, often multi-specialty groups. This trend, now more than a decade in the making, has accelerated meaningfully since 2020. What began as a handful of pioneering PE-backed platforms has grown into a structured ecosystem of nine major national and regional players, each pursuing a concentric market-building strategy designed to achieve clinical density, operational scale, and payer leverage within defined geographic footprints.

The Anatomy of a Roll-Up

Regional roll-ups in women’s health follow a well-established playbook. A private equity sponsor identifies an anchor or “platform” practice, typically a group with $5 million or more in normalized EBITDA, strong physician leadership, and documented operational infrastructure. The platform transaction is typically structured as a majority recapitalization, giving the PE firm control while incentivizing the founding physicians through rollover equity in the combined entity. From that foundation, the sponsor executes a series of “add-on” acquisitions, integrating smaller practices into the platform at lower multiples. The aggregated entity, once scaled, can command multiples of 12x to 14x EBITDA or more at sale, generating substantial returns through multiple arbitrage and EBITDA growth.

The Multi-Specialty Expansion Thesis

The leading women’s health platforms are increasingly moving beyond the traditional OB/GYN core. Unified Women’s Healthcare, Together Women’s Health, Women’s Care Enterprises, Axia Women’s Health, Femwell/VitalMD, and their peers are building integrated service ecosystems that include maternal-fetal medicine, reproductive endocrinology and infertility, urogynecology, gynecologic oncology, menopause care, aesthetics, and behavioral health. This multi-specialty approach serves dual strategic purposes: it enhances the patient relationship by offering comprehensive care under one roof, directly aligned with growing patient preferences for care consolidation, and it diversifies revenue streams, reducing dependence on any single reimbursement category.

Implications for Smaller Independent Practices

For independent OB/GYN practice owners, the roll-up trend creates both urgency and opportunity. On the urgency side, as regional platforms achieve scale, they gain material competitive advantages: superior payer contracts, broader clinical capabilities, stronger recruiting pipelines, shared administrative infrastructure, and the ability to absorb operational shocks. Independent practices that remain outside the consolidation trend may find themselves at an increasing disadvantage over time in markets where one or more regional platforms have established density. On the opportunity side, the same dynamics that make regional roll-ups strategically compelling for PE sponsors also make well-run independent practices valuable acquisition targets. The window to transact as a platform-tier asset, or as a strategically located add-on, remains open, but it is not indefinite.

A Fragmented Market Still Rich with Opportunity

Despite a decade of consolidation, the women’s health market remains highly fragmented. The $24 billion women’s health services industry in the U.S. remains dominated by independent and small-group practices, according to Bayshore Growth Partners’ April 2024 Women’s Health Sector Spotlight. This fragmentation represents a continuing opportunity for platform operators and a strategic inflection point for practice owners who are evaluating their long-term options. Understanding the regional competitive dynamics in your specific market is the first step toward making an informed decision about whether and when to engage in a strategic process.

An Investment Thesis Built on Fundamentals: Private equity firms do not allocate capital based on sentiment. They follow predictable, scalable cash flows, recurring revenue, and addressable markets large enough to support platform growth. Women’s health checks every one of those boxes. The global women’s health services market was valued at approximately $41.5 billion in 2022 and is projected to grow at more than 5% annually by 2030. The U.S. OB/GYN services segment alone encompasses a fragmented landscape of thousands of independent practices serving tens of millions of patients, exactly the kind of market structure that private equity consolidation strategies are designed to exploit.

Recurring Relationships and Predictable Volume

Unlike many healthcare specialties where patient encounters are episodic, OB/GYN practices benefit from long, longitudinal patient relationships. A woman’s relationship with her OB/GYN often begins in early adulthood with preventive and contraceptive care and continues through pregnancy, postpartum care, perimenopause, and beyond. This lifecycle engagement creates a highly predictable revenue base that PE underwriters value. Women visit doctors approximately 33% more frequently than men, generating substantial additional healthcare spending, according to AMB Wealth’s OB/GYN Industry Primer. That recurring, high-frequency visit pattern supports the kind of steady EBITDA generation that private equity sponsors rely on when modeling returns.

Cross-Sell and Service Line Expansion

Beyond core obstetrics and gynecology, women’s health platforms offer compelling cross-sell opportunities. Platforms are increasingly integrating labs, fertility services, aesthetic medicine, menopause care, behavioral health, and mammography into their service portfolios. According to Physician Growth Partners’ Q1 2025 white paper on women’s health private equity, practices offering ancillary services such as fertility treatment, mammography, and menopause care are experiencing accelerated consolidation activity. The Medical Group Management Association (MGMA) has found that practices that integrate ancillary services generate 15% to 25% higher net revenue per provider than those that do not. For a private equity sponsor underwriting a multi-year hold, each new service line represents both incremental EBITDA and a higher exit multiple.

Demographic Tailwinds and Supply Constraints

Demand for OB/GYN services is structurally growing. The average maternal age rose from 23.7 in 1985 to 29.6 in 2024, according to Cascade Partners, driving greater complexity and physician oversight requirements for an increasing share of pregnancies. Meanwhile, the supply side is constrained: the U.S. Health Resources & Services Administration projects a shortage of nearly 9,900 OB/GYNs by 2037. The combination of rising demand and constrained supply creates a durable pricing environment—a dynamic PE investors price favorably in their underwriting models. Over 500 hospitals have closed their obstetric units since 2010, accelerating patient migration to independent and consolidated practices.

The Opportunity

With nine major platforms now operating and more capital seeking entry, well-positioned independent practices represent valuable acquisition targets in an increasingly competitive market.